Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake ...

Current biomarkers of cognitive impairment in individuals with Alzheimer’s disease perform poorly. Now, a stronger predictor ...

New precision genome editing technologies are transforming the therapeutic landscape for patients with certain cancers and ...

Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...

The genetic code acts as life’s instruction manual, telling cells how to build proteins from DNA and RNA. Though it's a ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

March 27, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics ..

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment Full-year 2025 adjusted diluted EPS outlook ...